In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Selected Start-Ups (05/00)

Executive Summary

In Vivo summarizes the technologies of several recently founded companies: Avantium B.V., a joint venture of GSE Systems, Shell International Chemical, SmithKline Beecham, WR Grace & Co. and three Dutch universities, will employ high-speed experimentation and simulation technologies to speed product development in the chemical and pharmaceutical industries. Framingham Genomic Medicine will assemble, analyze and expand data from the Framingham Heart Study and make it available to pharmaceutical companies to aid in their drug discovery and development efforts. Ireland's HiberGen Ltd. will use SNaPIT, its proprietary SNP genotyping platform, to identify "disease genes" and conduct pharmacogenomic analysis in the development of individualized therapeutics and diagnostics. iMEDD Inc. will create therapeutic microdevices for delivering drugs directly to the part of the body where they are needed. Using a genomic based drug discovery platform licensed from Brown University, Nemogen Inc. will create pharmaceuticals for enhancing memory and learning. PointDX Inc. is developing integrated imaging analysis and reporting software which it claims will produce faster, cheaper, more accurate radiology reports than the current dictation or future voice recognition processes allow.

You may also be interested in...



Cambridge Vision Achieved, AstraZeneca Looks To Realize ‘Pipeline 2’ Ambitions

Having achieved a turnaround in its R&D and commercial fortunes, AstraZeneca’s hopes the opening of a new research center will herald its next wave of novel therapies.

Pfizer/BioNTech’s Comirnaty Supply Agreements Unaffected Despite EU Green Light For Under-12s

Pfizer and BioNTech’s Comirnaty supply under existing agreements will continue as planned despite anticipated expansion into a new child sub-population in Europe.

Novo Nordisk Braced For China Insulin Scheme Impact

The value-based procurement scheme in China is about to be implemented on insulin products and while most of Novo Nordisk's therapies were included in the tender, price cuts are going to impact global sales growth by 3% next year.

Related Companies

UsernamePublicRestriction

Register

IV001434

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel